Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer PHILADELPHIA and OXFORDSHIRE, United Kingdom

Adaptimmune Announces Appointment of

Michael Garone as Interim Chief Financial Officer

PHILADELPHIA and OXFORDSHIRE,

United Kingdom, October 1, 2019 -- Adaptimmune

Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces the appointment of Michael Garone as interim

Chief Financial Officer (CFO) effective immediately.

"We are thrilled to announce that Michael Garone will

be our interim CFO," said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer (CEO). "We are in the process

of selecting a permanent CFO and will communicate the outcome from that search in due course. In the meantime, Mike brings a depth

of expertise in the industry, including direct experience in oncology and immunotherapy with complex platforms. I look forward

to working with Mike in the months ahead."

Since the early 2000s, Mike has held various CFO positions in

the biotech and pharmaceutical industries. Most recently, Mike was CFO and interim CEO at Immunomedics, Inc., (Morris Plains, NJ)

where he supported the development phase of an Antibody Drug Conjugate (ADC) Oncology Product (IMMU-132/sacituzumab govitecan)

for the treatment of a broad range of solid tumors. While there, he supported the raise of more than $700 million in public and

private equity financings and a royalty financing. Prior to that, he was CFO at Emisphere Technologies, Inc. (Roseland, NJ) from

Mike began his career as an OTC stock trader with Drexel Burnham

Lambert in the early 1980s. From there, Mike went on to work at AT&T for twenty years where he held various positions of increasing

responsibility including CFO of AT&T Alascom.

The global search to select a permanent CFO is ongoing.

Adaptimmune is a clinical-stage biopharmaceutical company focused

on the development of novel cancer immunotherapy products for cancer patients. The Company's unique SPEAR (Specific Peptide

Enhanced Affinity Receptor) T-cell platform enables the engineering

of T-cells to target and destroy cancer across multiple solid tumors. For more information, please visit http://www.adaptimmune.com.

Adaptimmune Forward-Looking Statements

This release contains "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain

risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated

by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities

and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization

processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from

those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our

Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 1, 2019, and our other

SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made

and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts:

S bastien Desprez - VP, Communications and Investor

Juli P. Miller, Ph.D. - Senior Director, Investor Relations